Glioblastoma Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Glioblastoma stocks.

Glioblastoma Stocks Recent News

Date Stock Title
May 10 CLDX Celldex Therapeutics: Rising High, With Room For Further Growth
May 10 DCPH Here's What Key Metrics Tell Us About Deciphera Pharmaceuticals (DCPH) Q1 Earnings
May 10 DCPH Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Misses Revenue Estimates
May 9 RGLS Regulus Therapeutics GAAP EPS of -$0.29
May 9 RGLS Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates
May 9 CLDX Wall Street Analysts Believe Celldex (CLDX) Could Rally 67.77%: Here's is How to Trade
May 8 PSTV Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial
May 8 CLDX Celldex Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
May 8 CLRB Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day
May 7 CLRB Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024
May 6 CLDX Celldex GAAP EPS of -$0.56, revenue of $0.16M
May 6 CLDX Celldex Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 6 PSTV Plus Therapeutics looks to raise $18 million through private placement
May 6 RGLS Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
May 6 PSTV Plus Therapeutics Announces Private Placement Financing of up to $18 Million
Glioblastoma

Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive cancer that begins within the brain. Initially, signs and symptoms of glioblastoma are non-specific. They may include headaches, personality changes, nausea, and symptoms similar to those of a stroke. Worsening of symptoms often is rapid. This may progress to unconsciousness.The cause of most cases is unclear. Uncommon risk factors include genetic disorders such as neurofibromatosis and Li–Fraumeni syndrome, and previous radiation therapy. Glioblastomas represent 15% of brain tumors. They can either start from normal brain cells or develop from an existing low-grade astrocytoma. The diagnosis typically is made by a combination of CT scan, MRI scan, and tissue biopsy.There is no clear way to prevent the disease. Typically, treatment involves surgery, after which chemotherapy and radiation therapy are used. The medication temozolomide is used frequently as part of chemotherapy. High dose steroids may be used to help reduce swelling and decrease symptoms. It is unclear whether trying to remove all or simply most of the cancer is better.Despite maximum treatment, the cancer usually recurs. The most common length of survival following diagnosis is 12 to 15 months, with fewer than 3% to 5% of people surviving longer than five years. Without treatment, survival is typically three months. It is the most common cancer that begins within the brain and the second most common brain tumor, after meningioma. About 3 per 100,000 people develop the disease a year. It most often begins around 64 years of age and occurs more commonly in males than females. Immunotherapy is being studied.

Browse All Tags